IN2014DN07109A - - Google Patents

Info

Publication number
IN2014DN07109A
IN2014DN07109A IN7109DEN2014A IN2014DN07109A IN 2014DN07109 A IN2014DN07109 A IN 2014DN07109A IN 7109DEN2014 A IN7109DEN2014 A IN 7109DEN2014A IN 2014DN07109 A IN2014DN07109 A IN 2014DN07109A
Authority
IN
India
Prior art keywords
vgf
relates
qc1qr
tlqp
peptide
Prior art date
Application number
Other languages
English (en)
Inventor
Kenji Okuse
Alessandro Pristera
Original Assignee
Imp Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45876134&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014DN07109(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Imp Innovations Ltd filed Critical Imp Innovations Ltd
Publication of IN2014DN07109A publication Critical patent/IN2014DN07109A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IN7109DEN2014 2012-01-26 2013-01-25 IN2014DN07109A (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1201332.2A GB201201332D0 (en) 2012-01-26 2012-01-26 Method
PCT/GB2013/050162 WO2013110945A1 (en) 2012-01-26 2013-01-25 Methods of treating pain by inhibition of vgf activity

Publications (1)

Publication Number Publication Date
IN2014DN07109A true IN2014DN07109A (de) 2015-04-24

Family

ID=45876134

Family Applications (1)

Application Number Title Priority Date Filing Date
IN7109DEN2014 IN2014DN07109A (de) 2012-01-26 2013-01-25

Country Status (5)

Country Link
US (1) US9718879B2 (de)
EP (1) EP2807191B2 (de)
GB (1) GB201201332D0 (de)
IN (1) IN2014DN07109A (de)
WO (1) WO2013110945A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180100153A1 (en) * 2016-10-07 2018-04-12 Truebio LLC Method and kit for use in inhiiting tumor progression, predicting or determining tumor progression state in VGF expressing cancers
JP7748866B2 (ja) * 2021-12-13 2025-10-03 花王株式会社 痒みの検出方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0768377A1 (de) 1988-09-02 1997-04-16 Protein Engineering Corporation Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
AU662148B2 (en) 1991-04-10 1995-08-24 Scripps Research Institute, The Heterodimeric receptor libraries using phagemids
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
PT1696031E (pt) 1991-12-02 2010-06-25 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
JPH09506262A (ja) 1993-12-08 1997-06-24 ジェンザイム・コーポレイション 特異的抗体の製造方法
PT744958E (pt) 1994-01-31 2003-11-28 Univ Boston Bancos de anticorpos policlonais
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
MXPA02000678A (es) * 1999-07-21 2002-07-02 Amgen Inc Agentes de union selectivos para vgf y metodos para tratar desordenes relacionados con vgf.
EP1478772A2 (de) * 2001-08-14 2004-11-24 The General Hospital Corporation Nukleinsäure- und aminosäuresequenzen im zusammenhang mit schmerzen
TWI343377B (en) 2002-03-13 2011-06-11 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
US7993864B2 (en) 2002-12-03 2011-08-09 Ucb Pharma S.A. Assay for identifying antibody producing cells
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
HUE026278T2 (en) 2003-07-01 2016-05-30 Ucb Biopharma Sprl Modified Fab antibody fragments
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
TWI361066B (en) 2004-07-26 2012-04-01 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
CN102898364A (zh) 2005-05-18 2013-01-30 阵列生物制药公司 Mek的杂环抑制剂及其使用方法
CA2657649A1 (en) 2006-07-13 2008-08-21 Burnham Institute For Medical Research Methods and compositions for targeting gc1qr/p32
GB0616214D0 (en) 2006-08-15 2006-09-27 Ucb Sa Therapeutic Agents
GB0714384D0 (en) 2007-07-23 2007-09-05 Ucb Pharma Sa theraputic agents
GB0801081D0 (en) 2008-01-21 2008-02-27 Ucb Pharma Sa Therapeutic agents
GB0801080D0 (en) 2008-01-21 2008-02-27 Ucb Pharma Sa Therapeutic agents
WO2010111702A1 (en) 2009-03-27 2010-09-30 The Research Foundation Of State University Of New York Methods for preventing and treating angioedema
CN102458580A (zh) 2009-04-21 2012-05-16 诺瓦提斯公司 作为mek抑制剂的杂环化合物
PT2580322T (pt) 2010-06-09 2018-03-01 Dana Farber Cancer Inst Inc Uma mutação em mek1 que confere resistência aos inibidores de raf e mek

Also Published As

Publication number Publication date
EP2807191B2 (de) 2025-01-15
EP2807191B1 (de) 2019-07-10
WO2013110945A1 (en) 2013-08-01
EP2807191B8 (de) 2019-10-16
GB201201332D0 (en) 2012-03-14
US9718879B2 (en) 2017-08-01
US20140370024A1 (en) 2014-12-18
EP2807191A1 (de) 2014-12-03

Similar Documents

Publication Publication Date Title
WO2013188813A3 (en) Novel therapeutics for brain cancer
ZA202208792B (en) Methods of treating and preventing graft versus host disease
WO2015031564A3 (en) Substituted-1h-benzo[d]imidazole compounds as lysine-specific demethylase 1 (lsd1 ) inhibitors
MY163275A (en) Ibat inhibitors for the treatment of liver diseases
IN2015DN01197A (de)
IN2015DN01161A (de)
MX2020010535A (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
EP3354640A3 (de) Mif-hemmer und verwendungen davon
TN2012000555A1 (en) Antibodies to human gdf8
PH12015500832A1 (en) Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
MX2013008192A (es) Inhibidores de bace-2 para tratamiento de transtornos metabolicos.
EA201291357A1 (ru) Способы лечения с применением ингибиторов tlr7 и/или tlr9
PH12013500543A1 (en) Breast cancer therapeutics
IN2014CN02887A (de)
EA201491008A1 (ru) Комбинация антагониста crth2 и ингибитора протонного насоса для лечения эозинофильного эзофагита
IN2014DN10386A (de)
WO2012135697A3 (en) Novel rho kinase inhibitors and methods of use
MX360030B (es) Metodos para tratar el trastorno bipolar.
MX2013007603A (es) Antagonistas de hedgehog que tienen residuos que se unen al zinc.
HK1256042A1 (zh) 用於治疗糖尿病周围神经病变的hdac抑制剂
PH12014500925A1 (en) Therapeutic combinations and methods of treating melanoma
MX2019001977A (es) Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados.
AU2015279834A8 (en) Use of peptides that block metadherin-SND1 interaction as treatment for cancer
HK1257171A1 (zh) 间变性淋巴瘤激酶（alk）和丝氨酸富集蛋白激酶 （sppk）的抑制剂及其使用方法
MX2020001428A (es) Composiciones de grapiprant y metodos para usar las mismas.